N/A N=60 The Effects of Contact Lenses With Experimental Dye on Visual Function
Ametropia
Primary: Two-Point Light Spread Function — 5.36; 6.71; 6.47; 7.48 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=8 A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia
Anesthesia
Primary: Waking Time - Time Between Terminating Anesthesia and Subject Opening Eyes.
Phase 2 N=31 Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Relapse/Refractory Multiple Myeloma
Primary: Percentage of Participants With Near Complete Response (nCR)/ Complete Response (CR) Rate — 48.4 Percentage of participants — p=< 0.0001
Phase 2 N=11 Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Cognition Disorder · Attention Deficit Disorder · Traumatic Brain Injury
Primary: Perceptual Organization and Processing Speed Index — 89 score on a scale
Phase 3 N=394 A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Double-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA]) — NA; 22.29 Weeks — p=<0.001
N/A N=212 The Effectiveness of SMS in Improving Antiretroviral Medication Adherence Among Adolescents Living With HIV in Nigeria
HIV Infections
Primary: ART Adherence at 20 Weeks as Determined by VAS, Viral Load — 57; 47; 63; 46 Participants
Phase 1 N=41 Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 1; 1; 4; 3 Participants
N/A N=30 Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder
Hematologic Diseases · Secondary Immune Deficiency
Primary: Infusion Time of Multigam IV 5% and Multigam IV 10% — 4.92; 2.29 hour — p=<0.0001
Phase 2 N=42 Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma or Ocular Hypertension
Primary: Mean Diurnal IOP (Intraocular Pressure) (mmHg) — 14.35; 14.33; 17.32 mmHg
N/A N=21 In Vivo Kinematics for Subjects Implanted With Klassic Total Knee Arthroplasty (TKA)
Total Knee Arthroplasty · Osteo Arthritis Knee · Knee Implant
Primary: Axial Rotation (AR) During Deep Knee Bend — 6.6 degrees
N/A N=1,161 Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
Multiple Sclerosis
Primary: Number of Participants With Serious Adverse Drug Reactions (SADRs) — 1; 14 Participants
Phase 2 N=333 Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56
Myocardial Infarction · Percutaneous Coronary Intervention
Primary: Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI) — 71.0; 57.5; 62.4; 46.9 % of PRI
Phase 2 N=11 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma · Stage I Pancreatic Cancer
Primary: Number of Participants With Progressive Disease, — 2 Participants
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
Phase 2 N=22 The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic Rhinosinusitis
Rhinosinusitis
Primary: Change in Sino-nasal Outcome Test-22 Score Between Baseline and 6 Weeks, Then 6 Weeks to 12 Weeks. — 59.3; 52.9; 45.4; 51.8 units on a scale